Mizuno Yuri, Tada Yuji, Uehara Taira, Yamashita Satoshi, Murai Hiroyuki
Department of Neurology, International University of Health and Welfare Narita Hospital, Narita, JPN.
Department of Respirology, International University of Health and Welfare Narita Hospital, Narita, JPN.
Cureus. 2024 Dec 9;16(12):e75369. doi: 10.7759/cureus.75369. eCollection 2024 Dec.
( gene rearrangement-positive small-cell lung cancer (SCLC) is extremely rare. A 73-year-old man was diagnosed with SCLC. Standard treatments were not effective. Furthermore, at 74 years of age, intradural extramedullary metastases in the lumbar spinal cord and myelitis were observed. Autoimmune myelitis was suspected because anti-Zic4 antibodies were detected. However, steroid pulse therapy was ineffective. Interestingly, a novel rearrangement of the fusion gene was identified by blood-based next-generation sequencing. Although it was unclear whether the fusion gene was involved in tumor progression or an asymptomatic mutation, we treated the patient with alectinib, an ALK inhibitor; however, this therapy did not reduce the lesions. There is no established effective treatment for patients with SCLC who are fusion gene positive by liquid biopsy. Therefore, patient-specific approaches and treatments are required.
基因重排阳性的小细胞肺癌(SCLC)极为罕见。一名73岁男性被诊断为SCLC。标准治疗无效。此外,在74岁时,观察到腰椎脊髓硬膜内髓外转移和脊髓炎。由于检测到抗Zic4抗体,怀疑是自身免疫性脊髓炎。然而,类固醇脉冲疗法无效。有趣的是,通过基于血液的下一代测序鉴定出一种新的融合基因重排。虽然尚不清楚该融合基因是否参与肿瘤进展或无症状突变,但我们用ALK抑制剂阿来替尼治疗了该患者;然而,这种治疗并未减少病灶。对于通过液体活检检测为融合基因阳性的SCLC患者,尚无既定的有效治疗方法。因此,需要针对患者的个体化方法和治疗。